Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer

Biomarkers in Medicine

Volumn 5, Issue 1, 2011, Pages 87-91

  Shaw, Jacqui A ^a   Brown, James ^a   Coombes, R Charles ^b   Jacob, Jimmy ^b   Payne, Rachel ^b   Lee, Belinda ^b   Page, Karen ^a   Hava, Natasha ^b   Stebbing, Justin ^b,c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

biomarker; breast cancer; circulating tumor cells; minimal residual disease; plasma DNA

Indexed keywords

DNA FRAGMENT;

ARTICLE; BREAST CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; GAPDH GENE; GENE; GENE AMPLIFICATION; HER2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NODULE; NUCLEOTIDE SEQUENCE; ONCOLOGICAL PARAMETERS; PLASMA DNA CONCENTRATION;

BREAST NEOPLASMS; DNA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MULTIPLE PULMONARY NODULES; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 79951798346     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.118     Document Type: Article

References (27)

1. Cristofanilli M, Budd GT, Ellis MJ et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004). (Pubitemid 39095313)
2. Cristofanilli M, Hayes DF, Budd GT et al.: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23, 1420-1430 (2005).
3. Budd GT, Cristofanilli M, Ellis MJ et al.: Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12, 6403-6409 (2006). (Pubitemid 44799711)
4. Stathopoulou A, Vlachonikolis I, Mavroudis D et al.: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20, 3404-3412 (2002).
5. Benoy IH, Elst H, Philips M et al.: Real-time RT-PCR detection of disseminated tumor cells in bone marrow has superior prognostic significance in comparison with circulating tumor cells in patients with breast cancer. Br. J. Cancer 94, 672-680 (2006). (Pubitemid 43361898)
6. Gervasoni A, Monasterio Munoz RM, Wengler GS, Rizzi A, Zaniboni A, Parolini O: Molecular signature detection of circulating tumor cells using a panel of selected genes. Cancer Lett. 263, 267-279 (2008).
7. Smith BM, Slade MJ, English J et al.: Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J. Clin. Oncol. 18, 1432-1439 (2000). (Pubitemid 30205388)
8. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M: Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br. J. Cancer 92, 906-912 (2005). (Pubitemid 40462638)
9. Pachmann K, Clement JH, Schneider CP et al.: Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin. Chem. Lab. Med. 43, 617-627 (2005). (Pubitemid 41460612)
10. Pachmann K, Camara O, Kavallaris A et al.: Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J. Clin. Oncol. 26, 1208-1215 (2008).
11. Apostolopoulos C, Giamas G, Stebbing J: Clinical significance of circulating tumor cells. Biomark. Med. 1, 9-11 (2007).
12. Rack BK, Schindlbeck A, Schneeweiss J et al.: Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the German SUCCESS-Trial. Presented at: ASCO Annual Meeting 2008. Chicago, IL, USA, 30 May-3 June 2008.
13. Payne RE, Yague E, Slade MJ et al.: Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10, 51-57 (2009).
14. Slade MJ, Coombes RC: The clinical significance of disseminated tumor cells in breast cancer. Nat. Clin. Pract. Oncol. 4, 30-41 (2007). (Pubitemid 46017692)
15. Wang BG, Huang HY, Chen YC et al.: Increased plasma DNA integrity in cancer patients. Cancer Res. 63, 3966-3968 (2003). (Pubitemid 36917913)
16. Page K, Powles T, Slade MJ et al.: The importance of careful blood processing in isolation of cell-free DNA. Ann. NY Acad. Sci. 1075, 313-317 (2006). (Pubitemid 44532799)
17. Deligezer U, Eralp Y, Akisik EE et al.: Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin. Chem. Lab. Med. 46, 311-317 (2008). (Pubitemid 351317779)
18. Deligezer U, Eralp Y, Akisik EZ et al.: Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann. NY Acad. Sci. 1137, 175-179 (2008).
19. Shaw JA, Smith BM, Walsh T et al.: Microsatellite alterations plasma DNA of primary breast cancer patients. Clin. Cancer Res. 6, 1119-1124 (2000). (Pubitemid 30159375)
20. Van der Auwera I, Elst HJ, Van Laere SJ et al.: The presence of circulating total DNA and methylated genes is associated with circulating tumor cells in blood from breast cancer patients. Br. J. Cancer 100, 1277-1286 (2009).
21. Lee B, Lim A, Lalvani A et al.: The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann. Oncol. 19, 2001-2006 (2008).
22. Jiao L, Apostolopolous C, Stebbing J: Circulating tumor cells as new biomarkers in cancer. Adv. Cancer 59-63 (2008).
23. Mudan S, Giakoustidis A, Thillainayagam AV, Jacob J, Stebbing J: Clinical utility of circulating tumor cell measurement in the diagnosis of indeterminate lesions of the pancreas. Future Oncol. 6(1), 177-179 (2010).
24. Stebbing J, Jiao LR: Circulating tumor cells as more than prognostic markers. Lancet Oncol. 10, 1138-1139 (2009).
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor Marker prognostic studies (REMARK). Nat. Clin. Pract. Urol. 2, 416-422 (2005). (Pubitemid 43115010)
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor Marker prognostic studies (REMARK). Breast Cancer Res. Treat. 100, 229-235 (2006). (Pubitemid 44631925)
27. Jiao LR, Apostolopoulos C, Jacob J et al.: Unique localization of circulating tumor cells in patients with hepatic metastases. J. Clin. Oncol. 27, 6160-6165 (2009).